Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition

NCT01565278 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2016-05-12

No results posted yet for this study

Summary

Patients who are not able to eat normally for a longer time require parenteral nutrition, i.e. they receive liquids and nutrients directly into their veins. This can have many long-term side effects, including liver problems. This study will examine whether a specific lipid emulsion containing fish oil can improve liver disease in patients on parenteral nutrition. The investigators will compare changes in bilirubin and liver enzymes after 3 months in 10 patients receiving standard lipid emulsion to 10 patients receiving standard lipids + a fish-oil containing emulsion. The investigators will also assess liver histology, the kind of fat, oxidative stress and gene expression in the liver at the beginning and after 6 months of fish-oil. The investigators also want to compare the baseline values from all 20 patients to 20 healthy controls. This will help to explain how fish oil may improve liver disease in patients on parenteral nutrition.

Conditions

  • Total Parenteral Nutrition-induced Cholestasis

Interventions

DRUG

Soybean oil (Standard treatment)

1\. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day

DRUG

Soybean oil + Fish oil

Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months

Sponsors & Collaborators

  • ASPEN Rhoads Research Foundation

    collaborator INDUSTRY
  • Fresenius Kabi

    collaborator INDUSTRY
  • University of Alberta

    collaborator OTHER
  • Foothills Medical Centre

    collaborator OTHER
  • St. Boniface Hospital

    collaborator OTHER
  • Hamilton Health Sciences Corporation

    collaborator OTHER
  • St. Paul's Hospital, Canada

    collaborator OTHER
  • Johane Allard

    lead OTHER

Principal Investigators

  • Johane P Allard, MD,FRCPC · University Health Network, Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01565278 on ClinicalTrials.gov